FibroBiologics to Present at the BIO Investment & Growth Summit

Rhea-AI Summary

FibroBiologics (Nasdaq: FBLG) announced its Founder and CEO, Pete O’Heeron, will present at the BIO Investment & Growth Summit March 2-3, 2026, at Eden Roc, Miami Beach. The company presentation is scheduled for 10:15 a.m. ET on Monday, March 2, and management will hold one-on-one meetings during the event.

Investors can obtain more information via the company website or by contacting info@fibrobiologics.com; social channels include LinkedIn, YouTube, Facebook and X.

Key Figures

Patents portfolio: 270+ patents Summit dates: March 2–3, 2026 Presentation time: 10:15 a.m. ET

3 metrics

Patents portfolio 270+ patents Issued and pending, as described in company overview

Summit dates March 2–3, 2026 BIO Investment & Growth Summit schedule

Presentation time 10:15 a.m. ET Company presentation slot on March 2, 2026

Market Reality Check

Price: $0.2633 Vol: Volume 704,547 vs 20-day ...

normal vol

$0.2633 Last Close

Volume Volume 704,547 vs 20-day average 927,507 indicates lighter trading activity ahead of this event news. normal

Technical Price at 0.2633 is trading below the 200-day MA of 0.5, indicating a longer-term downtrend into this update.

Peers on Argus

Momentum scanner shows mixed moves among peers: ICU up 3.24%, while QTTB, NRXS, ...

1 Up 3 Down

Momentum scanner shows mixed moves among peers: ICU up 3.24%, while QTTB, NRXS, and GDTC are down between 4.44% and 6.48%. With multiple names flagged, this points to broader sector dynamics rather than a company-only driver.

Historical Context

5 past events · Latest: Feb 24 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 24	Earnings and update	Neutral	-1.6%	Full-year 2025 results and pipeline plus financing and debt update.
Feb 23	Nasdaq extension	Positive	+2.0%	Nasdaq Hearings Panel grants extension to regain listing compliance.
Feb 10	Conference presentation	Positive	+6.2%	CEO selected to present at A4LI H-SPAN Summit main stage.
Feb 05	Patent issuance	Positive	-9.2%	Canadian patent granted for fibroblast-based cachexia treatment platform.
Jan 20	Investor conference	Neutral	-3.7%	CEO to present at DealFlow Discovery Conference and meet investors.

Pattern Detected

Recent operational and event-driven headlines have produced mixed price reactions, with some positive news followed by negative moves and vice versa.

Recent Company History

Over the past months, FibroBiologics reported 2025 financial results with pipeline progress, secured a Nasdaq compliance extension with specific equity and bid-price targets, and announced multiple conference presentations and a Canadian patent. These updates occurred alongside capital structure actions and volatility around listings. Today’s conference presentation announcement fits into this pattern of visibility-building and corporate updates rather than a discrete financial or clinical inflection.

Market Pulse Summary

This announcement highlights FibroBiologics’ participation in the BIO Investment & Growth Summit, wi...

Analysis

This announcement highlights FibroBiologics’ participation in the BIO Investment & Growth Summit, with a company presentation on March 2, 2026 at 10:15 a.m. ET and one-on-one meetings. It follows recent financial results, Nasdaq compliance updates, and patent and conference news. Investors may watch how the company communicates its fibroblast platform, capital needs, and clinical milestones, especially given its position below the 0.5 200-day moving average and near the lower end of its 52-week range.

Key Terms

fibroblasts

1 terms

fibroblasts medical

"using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief"

Fibroblasts are common cells in connective tissue that manufacture the structural proteins and fibers—like collagen—that form and repair the body's scaffolding, helping wounds heal and tissues hold their shape. For investors, fibroblasts matter because they are frequent targets or tools in drug development, regenerative medicine and safety testing: changes in their behavior can signal whether a therapy will work, cause side effects or enable new medical products, much like a construction crew determines the strength and finish of a building.

AI-generated analysis. Not financial advice.

HOUSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the BIO Investment & Growth Summit taking place March 2-3, 2026, at the Eden Roc in Miami Beach, FL.

FibroBiologics will deliver a company presentation at 10:15 a.m. ET on Monday, March 2 and will be available for one-on-one meetings throughout the event.

For more information, please visit FibroBiologics’ website, email FibroBiologics at info@fibrobiologics.com or follow FibroBiologics on LinkedIn, YouTube, Facebook or X.

About FibroBiologics

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.

General Inquiries:
info@fibrobiologics.com

Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com

Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com

FAQ

When will FibroBiologics (FBLG) present at the BIO Investment & Growth Summit in 2026?

FibroBiologics will present at 10:15 a.m. ET on Monday, March 2, 2026. According to the company, CEO Pete O’Heeron is the scheduled presenter and the presentation occurs during the Eden Roc, Miami Beach summit running March 2–3, 2026.

Who from FibroBiologics (FBLG) will present at the BIO Investment & Growth Summit March 2026?

Founder and CEO Pete O’Heeron will present on behalf of FibroBiologics. According to the company, management will also be available for one-on-one investor meetings throughout the March 2–3, 2026 event at Eden Roc.

How can investors schedule one-on-one meetings with FibroBiologics (FBLG) at the March 2026 summit?

Investors can request one-on-one meetings through the company’s contact channels ahead of the event. According to the company, interested parties should email info@fibrobiologics.com or use the investor relations contacts listed on the company website.

Where is the BIO Investment & Growth Summit where FibroBiologics (FBLG) will present?

The summit takes place at Eden Roc in Miami Beach, Florida, March 2–3, 2026. According to the company, FibroBiologics’ presentation is scheduled for 10:15 a.m. ET on March 2, with management onsite for meetings during the conference.

Will FibroBiologics (FBLG) share presentation materials or webcasts from the March 2, 2026 session?

The company indicates attendees can find additional information via its website and social channels. According to the company, presentation materials or recordings may be posted to FibroBiologics’ website, LinkedIn, YouTube, Facebook or X after the event.

How can I contact FibroBiologics (FBLG) for investor information related to the BIO Summit?

Contact FibroBiologics via email at info@fibrobiologics.com for investor inquiries about the summit. According to the company, the investor relations information and social media channels provide additional access and updates surrounding the March 2–3, 2026 presentation.